Regarding safety outcomes, including estimated mean body weight change, overall hypoglycemia, adverse events related to Insulin, hypersensitivity, and injection site reactions, there were no significant differences in risk between the two Insulin regimens. This evidence concerns the gene INS and Hypoglycemia.